Literature DB >> 15550560

IL-7 exacerbates chronic colitis with expansion of memory IL-7Rhigh CD4+ mucosal T cells in mice.

Eriko Okada1, Motomi Yamazaki, Masanobu Tanabe, Tsutomu Takeuchi, Masanobu Nanno, Shigeru Oshima, Ryuichi Okamoto, Kiichiro Tsuchiya, Tetsuya Nakamura, Takanori Kanai, Toshifumi Hibi, Mamoru Watanabe.   

Abstract

We have previously demonstrated that mucosal CD4(+) T cells expressing high levels of IL-7 receptor (IL-7R(high)) are pathogenic cells responsible for chronic colitis. Here we investigate whether IL-7 is directly involved in the expansion of IL-7R(high) memory CD4(+) mucosal T cells and the exacerbation of colitis. We first showed that CD4(+) lamina propria lymphocytes (LPLs) from wild-type, T cell receptor-alpha-deficient (TCR-alpha(-/-)), and recombinase-activating gene (RAG)-2(-/-)-transferred mice with or without colitis showed phenotypes of memory cells, but only CD4(+) LPLs from colitic mice showed IL-7R(high). In vitro stimulation by IL-7, but not by IL-15 and thymic stromal lymphopoietin, enhanced significant proliferative responses and survival of colitic CD4(+), but not normal CD4(+) LPLs. Importantly, in vivo administration of IL-7 mice accelerated the expansion of IL-7R(high) memory CD4(+) LPLs and thereby exacerbated chronic colitis in RAG-2(-/-) mice transferred with CD4(+) LPLs from colitic TCR-alpha(-/-) mice. Conversely, the administration of anti-IL-7R monoclonal antibody significantly inhibited the development of TCR-alpha(-/-) colitis with decreased expansion of CD4(+) LPLs. Collectively, the present data indicate that IL-7 is essential for the expansion of pathogenic memory CD4(+) T cells under pathological conditions. Therefore, therapeutic approaches targeting the IL-7R pathway may be feasible in the treatment of human inflammatory bowel disease.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15550560     DOI: 10.1152/ajpgi.00276.2004

Source DB:  PubMed          Journal:  Am J Physiol Gastrointest Liver Physiol        ISSN: 0193-1857            Impact factor:   4.052


  9 in total

1.  IL-7 receptor influences anti-TNF responsiveness and T cell gut homing in inflammatory bowel disease.

Authors:  Lyssia Belarif; Richard Danger; Laetitia Kermarrec; Véronique Nerrière-Daguin; Sabrina Pengam; Tony Durand; Caroline Mary; Elise Kerdreux; Vanessa Gauttier; Aneta Kucik; Virginie Thepenier; Jerome C Martin; Christie Chang; Adeeb Rahman; Nina Salabert-Le Guen; Cécile Braudeau; Ahmed Abidi; Grégoire David; Florent Malard; Celine Takoudju; Bernard Martinet; Nathalie Gérard; Isabelle Neveu; Michel Neunlist; Emmanuel Coron; Thomas T MacDonald; Pierre Desreumaux; Hoa-Le Mai; Stephanie Le Bas-Bernardet; Jean-François Mosnier; Miriam Merad; Régis Josien; Sophie Brouard; Jean-Paul Soulillou; Gilles Blancho; Arnaud Bourreille; Philippe Naveilhan; Bernard Vanhove; Nicolas Poirier
Journal:  J Clin Invest       Date:  2019-04-02       Impact factor: 14.808

2.  Thymic stromal lymphopoetin-induced expression of the endogenous inhibitory enzyme SLPI mediates recovery from colonic inflammation.

Authors:  Colin Reardon; Matthias Lechmann; Anne Brüstle; Mélanie G Gareau; Naomi Shuman; Dana Philpott; Steven F Ziegler; Tak W Mak
Journal:  Immunity       Date:  2011-08-04       Impact factor: 31.745

3.  Aryl Hydrocarbon Receptor Activation Down-Regulates IL-7 and Reduces Inflammation in a Mouse Model of DSS-Induced Colitis.

Authors:  Tao Ji; Chao Xu; Lihua Sun; Min Yu; Ke Peng; Yuan Qiu; Weidong Xiao; Hua Yang
Journal:  Dig Dis Sci       Date:  2015-03-24       Impact factor: 3.199

4.  Low and undetectable breast milk interleukin-7 concentrations are associated with reduced risk of postnatal HIV transmission.

Authors:  Jan Walter; Louise Kuhn; Mrinal K Ghosh; Chipepo Kankasa; Katherine Semrau; Moses Sinkala; Mwiya Mwiya; Donald M Thea; Grace M Aldrovandi
Journal:  J Acquir Immune Defic Syndr       Date:  2007-10-01       Impact factor: 3.731

Review 5.  Recent advances in basic and clinical aspects of inflammatory bowel disease: which steps in the mucosal inflammation should we block for the treatment of inflammatory bowel disease?

Authors:  Hitoshi Asakura; Kenji Suzuki; Terasu Honma
Journal:  World J Gastroenterol       Date:  2007-04-21       Impact factor: 5.742

6.  Interleukin-7 receptor blockade suppresses adaptive and innate inflammatory responses in experimental colitis.

Authors:  Cynthia R Willis; Audrey Seamons; Joe Maxwell; Piper M Treuting; Laurel Nelson; Guang Chen; Susan Phelps; Carole L Smith; Thea Brabb; Brian M Iritani; Lillian Maggio-Price
Journal:  J Inflamm (Lond)       Date:  2012-10-12       Impact factor: 4.981

7.  CD127 expression inversely correlates with FoxP3 and suppressive function of human CD4+ T reg cells.

Authors:  Weihong Liu; Amy L Putnam; Zhou Xu-Yu; Gregory L Szot; Michael R Lee; Shirley Zhu; Peter A Gottlieb; Philipp Kapranov; Thomas R Gingeras; Barbara Fazekas de St Groth; Carol Clayberger; David M Soper; Steven F Ziegler; Jeffrey A Bluestone
Journal:  J Exp Med       Date:  2006-07-03       Impact factor: 14.307

8.  Oral Administration of Lactobacillus rhamnosus GG Ameliorates Salmonella Infantis-Induced Inflammation in a Pig Model via Activation of the IL-22BP/IL-22/STAT3 Pathway.

Authors:  Gui-Yan Yang; Jiao Yu; Jin-Hui Su; Lian-Guo Jiao; Xiao Liu; Yao-Hong Zhu
Journal:  Front Cell Infect Microbiol       Date:  2017-07-18       Impact factor: 5.293

9.  Influence of orally fed a select mixture of Bacillus probiotics on intestinal T-cell migration in weaned MUC4 resistant pigs following Escherichia coli challenge.

Authors:  Gui-Yan Yang; Yao-Hong Zhu; Wei Zhang; Dong Zhou; Cong-Cong Zhai; Jiu-Feng Wang
Journal:  Vet Res       Date:  2016-07-16       Impact factor: 3.683

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.